S. Korea Reports Makers Charge Higher Prices For H1N1 Flu Vaccine
This article was originally published in PharmAsia News
Executive Summary
South Korea expects to have enough H1N1 flu vaccine on hand to begin inoculations in November, at a cost of $155 million. The Korea Center For Disease Control and Prevention plans mass vaccinations with priority to certain sectors of the population. An immunization advisory committee currently is engaged in price negotiations with suppliers, and plans meetings to determine the priority groups. Officials say vaccine manufacturers in South Korea and abroad are demanding a price higher than the government had planned to pay, possibly delaying the inoculations for some South Koreans. (Click here for more
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.